De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Syngene International Beheer
Beheer criteriumcontroles 2/4
De CEO Syngene International's is Jonathan Hunt, benoemd in Jan2016, heeft een ambtstermijn van 8.75 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 285.33M, bestaande uit 50% salaris en 50% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.062% van de aandelen van het bedrijf, ter waarde ₹ 225.30M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 6.2 jaar.
Belangrijke informatie
Jonathan Hunt
Algemeen directeur
₹285.3m
Totale compensatie
| Percentage CEO-salaris | 50.0% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 0.06% |
| Management gemiddelde ambtstermijn | 7.7yrs |
| Gemiddelde ambtstermijn bestuur | 6.2yrs |
Recente managementupdates
Recent updates
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Is Syngene International (NSE:SYNGENE) Using Too Much Debt?
Aug 28Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate
Aug 10These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well
May 10Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Feb 02Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Nov 26Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly
Sep 21Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock
Aug 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹5b |
| Mar 31 2024 | ₹285m | ₹143m | ₹5b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹5b |
| Mar 31 2023 | ₹85m | ₹85m | ₹5b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹76m | ₹76m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹65m | ₹65m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹4b |
| Sep 30 2020 | n/a | n/a | ₹4b |
| Jun 30 2020 | n/a | n/a | ₹4b |
| Mar 31 2020 | ₹66m | ₹66m | ₹4b |
| Dec 31 2019 | n/a | n/a | ₹4b |
| Sep 30 2019 | n/a | n/a | ₹4b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹90m | ₹47m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹94m | ₹47m | ₹3b |
Compensatie versus markt: De totale vergoeding ($USD 3.40M ) Jonathan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 591.73K ).
Compensatie versus inkomsten: De vergoeding van Jonathan is het afgelopen jaar met meer dan 20% gestegen.
CEO
Jonathan Hunt (55 yo)
8.8yrs
Tenure
₹285,330,000
Compensatie
Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, CEO & Executive Director | 8.8yrs | ₹285.33m | 0.062% ₹ 225.3m | |
| CFO & Executive Director | 4.8yrs | ₹34.14m | 0.017% ₹ 61.9m | |
| Head of Investor Relations | no data | geen gegevens | 0.0016% ₹ 5.7m | |
| Head of Legal | 5.3yrs | ₹4.72m | 0.0024% ₹ 8.7m | |
| Head of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Head of Pharmaceutical & Biopharmaceutical Development | no data | ₹10.80m | geen gegevens | |
| Head of Formulations Development | no data | ₹5.50m | 0.025% ₹ 90.9m | |
| Head of IT | 8.7yrs | geen gegevens | 0.00038% ₹ 1.4m | |
| Head of Discovery Biology | 8.8yrs | geen gegevens | 0% ₹ 0 | |
| Head of Clinical Development & Stability Studies | 8.8yrs | geen gegevens | 0.0060% ₹ 21.8m | |
| Head of EHSS | 6.8yrs | geen gegevens | 0.0093% ₹ 34.1m |
7.7yrs
Gemiddelde duur
Ervaren management: Het managementteam van SYNGENE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, CEO & Executive Director | 7.4yrs | ₹285.33m | 0.062% ₹ 225.3m | |
| CFO & Executive Director | less than a year | ₹34.14m | 0.017% ₹ 61.9m | |
| Non-Executive Director | 24.2yrs | ₹8.28m | 0.0022% ₹ 8.0m | |
| Non-Executive Chairperson | no data | ₹9.43m | 0.0055% ₹ 20.0m | |
| Lead Independent Director | 7.3yrs | ₹8.62m | geen gegevens | |
| Independent Director | 7.6yrs | ₹7.46m | 0.012% ₹ 45.5m | |
| Additional Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non Executive Director | 3.3yrs | ₹6.47m | geen gegevens | |
| Non-Executive Independent Director | 10.2yrs | ₹9.12m | 0.012% ₹ 45.5m | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Additional Independent Director | 5.2yrs | ₹8.46m | geen gegevens |
6.2yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SYNGENE wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).